JP2020530440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530440A5 JP2020530440A5 JP2020500113A JP2020500113A JP2020530440A5 JP 2020530440 A5 JP2020530440 A5 JP 2020530440A5 JP 2020500113 A JP2020500113 A JP 2020500113A JP 2020500113 A JP2020500113 A JP 2020500113A JP 2020530440 A5 JP2020530440 A5 JP 2020530440A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- immune cell
- immune
- cell
- cytokine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002865 immune cell Anatomy 0.000 claims description 98
- 239000000203 mixture Substances 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 40
- 102000004127 Cytokines Human genes 0.000 claims description 35
- 108090000695 Cytokines Proteins 0.000 claims description 35
- 108091033319 polynucleotide Proteins 0.000 claims description 31
- 239000002157 polynucleotide Substances 0.000 claims description 31
- 102000040430 polynucleotide Human genes 0.000 claims description 31
- 239000003102 growth factor Substances 0.000 claims description 29
- 108020004999 messenger RNA Proteins 0.000 claims description 21
- -1 method Substances 0.000 claims description 20
- 230000008685 targeting Effects 0.000 claims description 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 16
- 230000004927 fusion Effects 0.000 claims description 16
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- 102000037865 fusion proteins Human genes 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 102100036302 C-C chemokine receptor type 6 Human genes 0.000 claims description 4
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 3
- 238000002659 cell therapy Methods 0.000 claims description 3
- 238000001890 transfection Methods 0.000 claims description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims description 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 claims description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 2
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 claims description 2
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 2
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 claims description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 2
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 claims description 2
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 2
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 2
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims description 2
- 101001018021 Homo sapiens T-lymphocyte surface antigen Ly-9 Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 2
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 102000000704 Interleukin-7 Human genes 0.000 claims description 2
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 102100029216 SLAM family member 5 Human genes 0.000 claims description 2
- 102100033447 T-lymphocyte surface antigen Ly-9 Human genes 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 238000004520 electroporation Methods 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 238000001638 lipofection Methods 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762528411P | 2017-07-03 | 2017-07-03 | |
| US62/528,411 | 2017-07-03 | ||
| US201762598433P | 2017-12-13 | 2017-12-13 | |
| US62/598,433 | 2017-12-13 | ||
| US201862620418P | 2018-01-22 | 2018-01-22 | |
| US201862620107P | 2018-01-22 | 2018-01-22 | |
| US62/620,107 | 2018-01-22 | ||
| US62/620,418 | 2018-01-22 | ||
| US201862657455P | 2018-04-13 | 2018-04-13 | |
| US62/657,455 | 2018-04-13 | ||
| PCT/US2018/040783 WO2019010222A2 (en) | 2017-07-03 | 2018-07-03 | POLYNUCLEOTIDES ENCODING IMMUNOSTIMULATING FUSION MOLECULES AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020530440A JP2020530440A (ja) | 2020-10-22 |
| JP2020530440A5 true JP2020530440A5 (https=) | 2021-08-12 |
Family
ID=64950351
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500048A Pending JP2020530280A (ja) | 2017-07-03 | 2018-07-03 | 免疫刺激性融合分子およびその使用 |
| JP2020500113A Pending JP2020530440A (ja) | 2017-07-03 | 2018-07-03 | 免疫刺激性融合分子をコードするポリヌクレオチドおよびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500048A Pending JP2020530280A (ja) | 2017-07-03 | 2018-07-03 | 免疫刺激性融合分子およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20200306301A1 (https=) |
| EP (3) | EP3675892A4 (https=) |
| JP (2) | JP2020530280A (https=) |
| KR (1) | KR20200037781A (https=) |
| CN (2) | CN111094330A (https=) |
| AU (4) | AU2018298063A1 (https=) |
| CA (3) | CA3068841A1 (https=) |
| GB (1) | GB2580228B (https=) |
| WO (3) | WO2019010222A2 (https=) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019008727A2 (pt) | 2016-11-28 | 2019-07-16 | Chugai Seiyaku Kabushiki Kaisha | domínio de ligação ao antígeno, e polipeptídeo incluindo seção de transporte |
| JP7626577B2 (ja) | 2016-11-28 | 2025-02-07 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| JP2020530280A (ja) | 2017-07-03 | 2020-10-22 | トルク セラピューティクス， インコーポレイテッド | 免疫刺激性融合分子およびその使用 |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| EP4029877B1 (en) | 2017-08-03 | 2024-01-17 | Amgen Inc. | Interleukin-21 muteins and methods of treatment |
| IL272635B2 (en) | 2017-09-06 | 2024-02-01 | Univ Yale | Variants of interleukin-18 and methods of use |
| JP7482630B2 (ja) | 2017-11-28 | 2024-05-14 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
| TWI880235B (zh) | 2017-11-28 | 2025-04-11 | 日商中外製藥股份有限公司 | 可調整配體結合活性的配體結合分子 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CA3100050A1 (en) | 2018-05-11 | 2019-11-14 | Lupagen, Inc. | Systems and methods for closed loop, real-time modifications of patient cells |
| CA3100349A1 (en) * | 2018-05-17 | 2019-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor inhibition by phosphatase recruitment |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CA3124688A1 (en) * | 2018-12-31 | 2020-07-09 | Merus N.V. | Truncated multivalent multimers |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| WO2020159656A1 (en) * | 2019-02-01 | 2020-08-06 | Actinium Pharmaceuticals, Inc. | Molecules and their derivatives directed against cd45 |
| EP4414033A3 (en) * | 2019-02-08 | 2024-10-30 | Biontech Cell & Gene Therapies Gmbh | Treatment involving car-engineered t cells and cytokines |
| WO2020165374A1 (en) * | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| EP3927728A2 (en) | 2019-02-21 | 2021-12-29 | Xencor, Inc. | Untargeted and targeted il-10 fc-fusion proteins |
| CN113710229B (zh) | 2019-02-25 | 2026-01-06 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| SG11202110810WA (en) * | 2019-03-29 | 2021-10-28 | Torque Therapeutics Inc | Immunotherapeutic compositions and use thereof |
| EP3969119A1 (en) | 2019-05-17 | 2022-03-23 | Xencor, Inc. | Il-7-fc-fusi0n proteins |
| BR112021023345A2 (pt) * | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| WO2020259536A1 (zh) * | 2019-06-24 | 2020-12-30 | 南京金斯瑞生物科技有限公司 | 单克隆抗体-细胞因子融合蛋白二聚体及其应用 |
| JP2022538139A (ja) * | 2019-07-02 | 2022-08-31 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 変異体インターロイキン－２及び抗ｃｄ８抗体を含む免疫複合体 |
| AU2020315213A1 (en) * | 2019-07-17 | 2022-02-03 | National University Of Singapore | Functional binders synthesized and secreted by immune cells |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| US20220289838A1 (en) * | 2019-08-19 | 2022-09-15 | Nantong Yichen Biopharma. Co. Ltd. | Immunocytokine, Preparation for the Same, and Uses Thereof |
| CN110731968A (zh) * | 2019-09-10 | 2020-01-31 | 南京鼓楼医院 | Icos+cxcr3+调节性t细胞在制备预防重症肺炎药物中的应用 |
| RU2753282C2 (ru) * | 2019-09-19 | 2021-08-12 | Закрытое Акционерное Общество "Биокад" | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ |
| EP3795583A1 (en) * | 2019-09-19 | 2021-03-24 | Ecole Polytechnique Federale de Lausanne (EPFL) | Il10/fc fusion proteins useful as enhancers of immunotherapies |
| IL292628A (en) | 2019-11-01 | 2022-07-01 | Magenta Therapeutics Inc | Anti-cd45 antibody and conjugates accordingly |
| US10792360B1 (en) * | 2019-11-21 | 2020-10-06 | Chemocentryx, Inc. | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
| US20230242655A1 (en) | 2019-12-03 | 2023-08-03 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| JP2023504884A (ja) * | 2019-12-05 | 2023-02-07 | ヴィセリックス・インコーポレーティッド | ユニバーサル細胞療法のための免疫逃避機構のモジュレーター |
| WO2021127487A2 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
| WO2021188835A1 (en) * | 2020-03-18 | 2021-09-23 | City Of Hope | Multivalent chemokine receptor binding complexes |
| IL298136A (en) | 2020-05-13 | 2023-01-01 | Bonum Therapeutics Inc | Preparations of protein complexes and methods of using them |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| WO2021242989A1 (en) * | 2020-05-29 | 2021-12-02 | Health Research, Inc. | Compositions and methods for inducing cas9 protein expression by use of autonomous pd-1 promoter activity |
| CN116322740A (zh) * | 2020-07-13 | 2023-06-23 | 特兰斯吉恩股份有限公司 | 免疫抑制的治疗 |
| WO2022040577A1 (en) * | 2020-08-20 | 2022-02-24 | City Of Hope | Compositions and uses of cd45 targeted chimeric antigen receptor modified t cells |
| US12071633B2 (en) | 2020-10-13 | 2024-08-27 | Kriya Therapeutics, Inc. | Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer |
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| AU2021389989A1 (en) * | 2020-11-27 | 2023-06-08 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel conjugate molecules targeting cd39 and tgfβeta |
| US12098178B2 (en) | 2020-12-04 | 2024-09-24 | Visterra, Inc. | Methods of using interleukin-2 agents |
| KR20230129983A (ko) * | 2020-12-09 | 2023-09-11 | 애셔 바이오테라퓨틱스, 인크. | 조작된 세포 요법을 위한 표적화된 사이토카인 구축물 |
| WO2022165260A1 (en) | 2021-01-29 | 2022-08-04 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
| JP2024506292A (ja) * | 2021-02-05 | 2024-02-13 | サルブリス バイオセラピューティクス，インコーポレイティド | Ｉｌ－１５融合タンパク質と、その製造法ならびに利用法 |
| CA3211501A1 (en) * | 2021-02-19 | 2022-08-25 | Janssen Biotech, Inc. | Materials and methods for targeting regulatory t cells for enhancing immune surveillance |
| KR20230147619A (ko) * | 2021-02-26 | 2023-10-23 | 난징 레전드 바이오테크 씨오., 엘티디. | 외인적으로 도입된 사이토카인을 발현하는 조작된 면역이펙터 세포 |
| MX2023011268A (es) | 2021-03-24 | 2023-12-14 | Alkermes Inc | Anticuerpos upar y proteínas de fusión con estos. |
| CN117836318A (zh) * | 2021-03-31 | 2024-04-05 | 加利福尼亚大学董事会 | 用于降解靶蛋白的双特异性结合剂-配体融合物 |
| KR102604849B1 (ko) * | 2021-05-11 | 2023-11-22 | 가톨릭대학교 산학협력단 | 항-cd25 항체, il-10 및 cxcr3를 발현하는 미니서클 벡터 |
| IL308609A (en) * | 2021-05-19 | 2024-01-01 | Asher Biotherapeutics Inc | IL-21 polypeptides and target constructs |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| CN113444744A (zh) * | 2021-06-28 | 2021-09-28 | 北京鼎成肽源生物技术有限公司 | 一种用于基因编辑NK细胞的mRNA模板及构建方法、mRNA的体外转录方法和应用 |
| CN117957258A (zh) | 2021-07-19 | 2024-04-30 | 中外制药株式会社 | 利用融合多肽的蛋白酶介导的靶向特异性细胞因子递送 |
| KR20240074772A (ko) * | 2021-10-10 | 2024-05-28 | 엘릭시론 이뮤노테라퓨틱스 (홍콩) 리미티드 | 항-pd-l1/il-10 융합 단백질을 이용한 질병 치료 방법 |
| EP4433512A4 (en) * | 2021-11-19 | 2025-12-31 | Univ Pennsylvania | Genetically modified pan-leukocyte-specific CD45 antigen to facilitate T-lymphocyte therapy |
| AU2022399832A1 (en) * | 2021-12-01 | 2024-06-06 | The Children's Hospital Of Philadelphia | Methods of using interleukin-2 agents |
| CN116376942A (zh) * | 2021-12-31 | 2023-07-04 | 广州国家实验室 | mRNA疫苗 |
| EP4463484A4 (en) * | 2022-01-14 | 2026-02-25 | Qilu Puget Sound Biotherapeutics Corp | Anti-ccr8 antibodies |
| EP4466290A4 (en) * | 2022-01-20 | 2026-02-11 | Repertoire Immune Medicines Inc | IL-12 FUSION PROTEINS TARGETING CD8 |
| EP4469065A1 (en) | 2022-01-28 | 2024-12-04 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
| JP2025510189A (ja) | 2022-03-24 | 2025-04-14 | アクティニウム ファーマシューティカルズ インコーポレイテッド | ヒト化抗ｃｄ４５抗体 |
| WO2023201008A1 (en) * | 2022-04-13 | 2023-10-19 | President And Fellows Of Harvard College | Compositions and methods for localized delivery of cytokines for adoptive cell therapy |
| CN119546343A (zh) * | 2022-04-27 | 2025-02-28 | 亚设生物治疗公司 | 细胞因子融合蛋白与cd8抗原结合分子的组合 |
| CN116854821A (zh) * | 2022-08-15 | 2023-10-10 | 海徕科(北京)生物技术有限公司 | IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途 |
| WO2024055040A2 (en) * | 2022-09-09 | 2024-03-14 | Actinium Pharmaceuticals, Inc. | Humanized anti-cd45 antibodies |
| WO2024078521A1 (zh) * | 2022-10-12 | 2024-04-18 | 苏州创胜医药集团有限公司 | 包含抗vegfr2抗体的制剂 |
| WO2024097307A1 (en) * | 2022-11-01 | 2024-05-10 | Lupagen, Inc. | Devices and methods for extracorporeal cell treatment |
| EP4634216A1 (en) | 2022-12-16 | 2025-10-22 | Repertoire Immune Medicines, Inc. | T cell receptors binding hpv-16 epitopes |
| WO2024178305A1 (en) * | 2023-02-24 | 2024-08-29 | Modernatx, Inc. | Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer |
| WO2024178414A2 (en) * | 2023-02-24 | 2024-08-29 | The Wistar Institute Of Anatomy And Biology | Epitope editing and multi-specific immunce-cell engager therapy and methods of use |
| AU2024258970A1 (en) * | 2023-04-17 | 2025-10-23 | ZAG Bio, Inc. | Tissue-directed antibodies and methods of using the same |
| WO2024254514A1 (en) * | 2023-06-08 | 2024-12-12 | The University Of North Carolina At Chapel Hill | Engineered antibody fusion proteins with modulable binding constants and their applications |
| WO2025072623A1 (en) * | 2023-09-28 | 2025-04-03 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting immune cells |
| WO2025080338A1 (en) * | 2023-10-11 | 2025-04-17 | Massachusetts Institute Of Technology | Cell-surface anchored cytokine therapy |
| WO2026015637A1 (en) * | 2024-07-10 | 2026-01-15 | The Trustees Of Dartmouth College | Treg targeted il-2 fusion proteins and therapeutic use thereof |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| US5405940A (en) | 1992-08-31 | 1995-04-11 | Ludwig Institute For Cancer Research | Isolated nonapeptides derived from MAGE genes and uses thereof |
| ES2590912T3 (es) | 1997-12-08 | 2016-11-24 | Merck Patent Gmbh | Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario |
| ES2267263T3 (es) | 1998-04-15 | 2007-03-01 | Emd Lexigen Research Center Corp. | Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo. |
| US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| US7550143B2 (en) | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US8383081B2 (en) | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
| US8119101B2 (en) | 1999-05-10 | 2012-02-21 | The Ohio State University | Anti-CD74 immunoconjugates and methods of use |
| MXPA02001417A (es) | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
| KR20030064275A (ko) | 2000-06-29 | 2003-07-31 | 메르크 파텐트 게엠베하 | 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강 |
| WO2002088334A1 (en) * | 2001-04-30 | 2002-11-07 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| DK1454138T3 (da) * | 2001-12-04 | 2012-02-13 | Merck Patent Gmbh | Immunocytokiner med moduleret selektivitet |
| WO2003061695A1 (en) | 2002-01-17 | 2003-07-31 | Amgen Inc. | Methods of regulating cytokine receptor signaling |
| US8287864B2 (en) | 2002-02-14 | 2012-10-16 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
| US20070003514A1 (en) | 2002-04-05 | 2007-01-04 | The Regents Of The University Of California | Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination |
| US7906118B2 (en) | 2005-04-06 | 2011-03-15 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology |
| US7615223B2 (en) | 2002-07-15 | 2009-11-10 | Board Of Regents, The University Of Texas System | Selected immunoconjugates for binding to aminophospholipids |
| EP1418184A1 (en) | 2002-11-08 | 2004-05-12 | Cell Center Cologne GmbH | Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof |
| KR20060041205A (ko) | 2003-07-01 | 2006-05-11 | 이뮤노메딕스, 인코오포레이티드 | 양특이성 항체들의 다가 담체들 |
| KR101225299B1 (ko) | 2003-12-10 | 2013-01-24 | 메다렉스, 인코포레이티드 | 인터페론 알파 항체 및 그의 용도 |
| US8652484B2 (en) | 2004-02-13 | 2014-02-18 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
| US8034352B2 (en) | 2005-04-06 | 2011-10-11 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
| US9550838B2 (en) | 2004-02-13 | 2017-01-24 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| US20110020273A1 (en) | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| US20120237442A1 (en) | 2005-04-06 | 2012-09-20 | Ibc Pharmaceuticals, Inc. | Design and Construction of Novel Multivalent Antibodies |
| US9931413B2 (en) | 2005-04-06 | 2018-04-03 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
| AU2006232310B9 (en) | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
| US8067006B2 (en) | 2005-04-06 | 2011-11-29 | Immunomedics, Inc. | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
| US9623115B2 (en) | 2005-04-06 | 2017-04-18 | Ibc Pharmaceuticals, Inc. | Dock-and-Lock (DNL) Complexes for Disease Therapy |
| CA2607954A1 (en) | 2005-05-11 | 2006-11-16 | Philogen S.P.A. | Conjugate for targeting of drug |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20100226884A1 (en) | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
| SG153825A1 (en) | 2005-12-16 | 2009-07-29 | Ibc Pharmaceuticals Inc | Multivalent immunoglobulin-based bioactive assemblies |
| PL1966238T3 (pl) | 2005-12-30 | 2012-09-28 | Merck Patent Gmbh | Warianty interleukiny-12p40 o polepszonej stabilności |
| US8450112B2 (en) * | 2008-04-09 | 2013-05-28 | Maxcyte, Inc. | Engineering and delivery of therapeutic compositions of freshly isolated cells |
| US9283184B2 (en) | 2008-11-24 | 2016-03-15 | Massachusetts Institute Of Technology | Methods and compositions for localized agent delivery |
| ES3000111T3 (en) | 2009-02-13 | 2025-02-27 | Immunomedics Inc | Intermediates for preparing conjugates with an intracellularly-cleavable linkage |
| EP2478110B1 (en) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| US20110165122A1 (en) * | 2009-11-10 | 2011-07-07 | The Regents Of The University Of California | Method for targeted and sustained antiviral therapy |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2011090492A1 (en) | 2010-01-19 | 2011-07-28 | Immunomedics, Inc. | Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r) |
| CN101829322A (zh) * | 2010-03-05 | 2010-09-15 | 孙嘉琳 | 细胞因子-超抗原融合蛋白在制备抗实体瘤药物的应用 |
| WO2011112935A2 (en) | 2010-03-12 | 2011-09-15 | The Regents Of The University Of California | Antibody fusion proteins with disrupted heparin-binding activity |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| EP2571992B1 (en) | 2010-05-21 | 2018-04-25 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
| US9150897B2 (en) * | 2010-08-06 | 2015-10-06 | The Regents Of The University Of California | Expression and purification of fusion protein with multiple MBP tags |
| US8507222B2 (en) * | 2010-09-21 | 2013-08-13 | Altor Bioscience Corporation | Multimeric IL-15 soluble fusion molecules and methods of making and using same |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2819074C (en) * | 2010-12-06 | 2020-04-14 | Shell Internationale Research Maatschappij B.V. | Process for removing mercaptans from a gas stream |
| EP2723380B1 (en) | 2011-06-24 | 2019-08-21 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| ES2872964T3 (es) | 2011-07-27 | 2021-11-03 | Philogen Spa | Inmunoconjugado de IL-12 |
| CA2841867A1 (en) | 2011-10-03 | 2013-04-11 | Celeste Aida S. Regino | Dye conjugated peptides for fluorescent imaging |
| EP3559049B1 (en) * | 2011-10-28 | 2025-06-11 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| CA2855566A1 (en) | 2011-12-02 | 2013-06-06 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors |
| PT2822575T (pt) * | 2012-03-03 | 2020-07-02 | Immungene Inc | Moléculas de fusão anticorpos-mutante de interferão modificadas |
| JP6385357B2 (ja) | 2012-11-27 | 2018-09-05 | アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ | 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途 |
| EP2970486B1 (en) | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| WO2014174105A1 (en) | 2013-04-25 | 2014-10-30 | Philochem Ag | Antibody-drug conjugates |
| KR102332303B1 (ko) | 2013-05-31 | 2021-11-26 | 자임워크스 인코포레이티드 | 감소되거나 침묵화된 효과기 기능을 갖는 이종다량체 |
| CA2953287A1 (en) | 2013-06-19 | 2014-12-24 | Massachusetts Institute Of Technology | In vivo targeting of cells with ligand-conjugated particles |
| US20160145355A1 (en) | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| AR096891A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
| CA3191031A1 (en) | 2013-09-27 | 2015-04-02 | Massachusetts Institute Of Technology | Carrier-free biologically-active protein nanostructures |
| DK3186283T3 (da) | 2014-08-29 | 2020-03-02 | Hoffmann La Roche | Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1 |
| EP3197911A4 (en) | 2014-09-22 | 2018-06-20 | Intrexon Corporation | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
| US20160176969A1 (en) | 2014-11-26 | 2016-06-23 | Xencor, Inc. | Heterodimeric antibodies including binding to cd8 |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| WO2016112983A1 (en) | 2015-01-15 | 2016-07-21 | Biontech Ag | Cytokine fusion proteins |
| US10227411B2 (en) * | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| US11022615B2 (en) | 2015-05-04 | 2021-06-01 | University Of Florida Research Foundation, Inc. | Regulatory T-cells, method for their isolation and uses |
| EP3297684B1 (en) | 2015-05-21 | 2020-12-23 | Actinium Pharmaceuticals, Inc. | Infusion administration of conjugated monoclonal antibodies |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| US11655452B2 (en) * | 2015-06-25 | 2023-05-23 | Icell Gene Therapeutics Inc. | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| WO2017027843A1 (en) | 2015-08-12 | 2017-02-16 | Massachusetts Institute Of Technology | Cell surface coupling of nanoparticles |
| WO2017062953A1 (en) | 2015-10-10 | 2017-04-13 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| WO2017102010A1 (en) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
| WO2017123627A1 (en) | 2016-01-11 | 2017-07-20 | Stc Biologics, Inc. | Bispecific targeting agents and methods for their preparation |
| CN116769054A (zh) | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| CN109562126A (zh) | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| US12304935B2 (en) | 2016-07-29 | 2025-05-20 | Juno Therapeutics, Inc. | Immunomodulatory polypeptides and related compositions and methods |
| US10696722B2 (en) | 2016-08-10 | 2020-06-30 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
| WO2018030806A1 (ko) | 2016-08-10 | 2018-02-15 | 아주대학교산학협력단 | 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물 |
| EP3523323A4 (en) | 2016-10-07 | 2020-06-17 | Board of Regents, The University of Texas System | T-CELLS WITH EXPRESSION OF MEMBRANE-ANCHORED IL-12 FOR THE TREATMENT OF CANCER |
| US20190352335A1 (en) | 2016-12-19 | 2019-11-21 | Hanmi Pharm. Co., Ltd. | Brain targeting long-acting protein conjugate |
| CN110545849A (zh) | 2017-02-03 | 2019-12-06 | 韩美药品株式会社 | 具有增加的持续性的生理活性物质的缀合物及其应用 |
| KR20190126182A (ko) | 2017-03-27 | 2019-11-08 | 난트셀, 인크. | aNK 및 IL-12 조성물 및 방법 (ANK AND IL-12 COMPOSITIONS AND METHODS) |
| JP7285220B2 (ja) | 2017-05-18 | 2023-06-01 | モデルナティエックス インコーポレイテッド | 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子 |
| EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| CA3287539A1 (en) | 2017-06-21 | 2026-03-02 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF |
| WO2019006472A1 (en) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
| JP2020530280A (ja) | 2017-07-03 | 2020-10-22 | トルク セラピューティクス， インコーポレイテッド | 免疫刺激性融合分子およびその使用 |
| WO2019129053A1 (zh) | 2017-12-26 | 2019-07-04 | 南京金斯瑞生物科技有限公司 | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 |
| AU2019228381B2 (en) | 2018-02-28 | 2021-12-16 | Pfizer Inc. | IL-15 variants and uses thereof |
| CN110396133B (zh) | 2018-04-25 | 2021-07-23 | 免疫靶向有限公司 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| CN112513276B (zh) | 2018-07-30 | 2024-03-15 | 张晋宇 | 蛋白质异二聚体及其用途 |
| CN120365435A (zh) | 2018-08-30 | 2025-07-25 | 免疫生物公司 | 单链嵌合多肽和多链嵌合多肽以及其用途 |
| MX2021003580A (es) | 2018-09-28 | 2021-10-13 | Pf Medicament | Nuevas inmunocitocinas para el tratamiento contra el cancer. |
| AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| CA3118943A1 (en) | 2018-11-15 | 2020-05-22 | Torque Therapeutics, Inc. | Methods and compositions for cancer immunotherapy |
| JP7178139B2 (ja) | 2018-12-11 | 2022-11-25 | オンコセック メディカル インコーポレイテッド | 免疫調節タンパク質発現のための多重遺伝子構築物および使用方法 |
| EP3897851A2 (en) | 2018-12-17 | 2021-10-27 | Revitope Limited | Twin immune cell engager |
| SG11202110810WA (en) | 2019-03-29 | 2021-10-28 | Torque Therapeutics Inc | Immunotherapeutic compositions and use thereof |
| CN111848810B (zh) | 2019-04-28 | 2024-08-23 | 张晋宇 | 一种蛋白质分子及其用途 |
| EP3980051A4 (en) | 2019-06-05 | 2023-09-13 | Asher Biotherapeutics, Inc. | FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS |
| US20250041386A1 (en) | 2019-06-18 | 2025-02-06 | Janssen Sciences Ireland Unlimited Company | Recombinant Interleukin 12 Construct and Uses Thereof |
| WO2020259536A1 (zh) | 2019-06-24 | 2020-12-30 | 南京金斯瑞生物科技有限公司 | 单克隆抗体-细胞因子融合蛋白二聚体及其应用 |
| JP2022538139A (ja) | 2019-07-02 | 2022-08-31 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 変異体インターロイキン－２及び抗ｃｄ８抗体を含む免疫複合体 |
| US20220306735A1 (en) | 2019-08-30 | 2022-09-29 | University Of Kansas | Compositions including igg fc mutations and uses thereof |
| AU2021208642B2 (en) | 2020-01-17 | 2025-06-05 | Immunelogic Therapeutics, Inc. | Pro-antibody that reduces off-target toxicity |
| EP3889183A1 (en) | 2020-04-01 | 2021-10-06 | Pierre Fabre Medicament | A protein complex comprising an immunocytokine |
-
2018
- 2018-07-03 JP JP2020500048A patent/JP2020530280A/ja active Pending
- 2018-07-03 CA CA3068841A patent/CA3068841A1/en active Pending
- 2018-07-03 JP JP2020500113A patent/JP2020530440A/ja active Pending
- 2018-07-03 GB GB2001438.7A patent/GB2580228B/en not_active Expired - Fee Related
- 2018-07-03 EP EP18828706.4A patent/EP3675892A4/en not_active Withdrawn
- 2018-07-03 US US16/628,363 patent/US20200306301A1/en not_active Abandoned
- 2018-07-03 AU AU2018298063A patent/AU2018298063A1/en not_active Abandoned
- 2018-07-03 CA CA3069105A patent/CA3069105A1/en active Pending
- 2018-07-03 WO PCT/US2018/040783 patent/WO2019010222A2/en not_active Ceased
- 2018-07-03 WO PCT/US2018/040777 patent/WO2019010219A1/en not_active Ceased
- 2018-07-03 AU AU2018298060A patent/AU2018298060B2/en not_active Ceased
- 2018-07-03 EP EP18827456.7A patent/EP3648786A4/en not_active Withdrawn
- 2018-07-03 CN CN201880056938.1A patent/CN111094330A/zh active Pending
- 2018-07-03 KR KR1020207003059A patent/KR20200037781A/ko not_active Abandoned
- 2018-07-03 US US16/628,374 patent/US20210017247A1/en not_active Abandoned
- 2018-07-03 EP EP18827557.2A patent/EP3649147A4/en not_active Withdrawn
- 2018-07-03 CN CN201880056956.XA patent/CN111093689A/zh active Pending
- 2018-07-03 CA CA3069017A patent/CA3069017A1/en active Pending
- 2018-07-03 WO PCT/US2018/040786 patent/WO2019010224A1/en not_active Ceased
- 2018-07-03 US US16/628,342 patent/US11471490B2/en active Active
- 2018-07-03 AU AU2018297248A patent/AU2018297248A1/en not_active Abandoned
-
2021
- 2021-05-17 AU AU2021203162A patent/AU2021203162A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530440A5 (https=) | ||
| Zheng et al. | The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy | |
| Overwijk et al. | Engineering IL-2 to give new life to T cell immunotherapy | |
| Rohaan et al. | Adoptive cellular therapies: the current landscape | |
| Wu et al. | Chimeric antigen receptor therapy meets mRNA technology | |
| US12304936B2 (en) | Interleukin 21 protein (IL21) mutant and encoding nucleic acid | |
| CN109952309B (zh) | 用于细胞治疗的组成型活性细胞因子受体 | |
| Redeker et al. | Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination | |
| Tzeng et al. | In situ genetic engineering of tumors for long-lasting and systemic immunotherapy | |
| Kim et al. | Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7 | |
| JP2020530280A5 (https=) | ||
| Uricoli et al. | Engineered cytokines for cancer and autoimmune disease immunotherapy | |
| CN104177499B (zh) | 一种嵌合抗原受体、编码基因、表达载体及其应用 | |
| TW201734205A (zh) | 表現免疫機能控制因子之免疫活性細胞及表現載體 | |
| WO1996010089A1 (en) | Modification of peptide and protein | |
| JP2018516913A5 (https=) | ||
| EP3720453B1 (en) | Modified lymphocytes | |
| AU2018277294A1 (en) | Oncolytic virus and method | |
| JP2024512608A5 (https=) | ||
| Borgers et al. | Cellular therapy and cytokine treatments for melanoma | |
| KR20210065065A (ko) | 단백질 발현용 mRNA 구조체 및 이의 용도 | |
| JP2025519106A (ja) | 脂質ナノ粒子用のターゲティング体を有する修飾アポリポタンパク質 | |
| TW202300643A (zh) | 用於增強幹細胞樣記憶ｔ細胞工程改造之材料及方法 | |
| US20220195441A1 (en) | Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias | |
| Bogacz et al. | Modern immunotherapy using CAR-T cells in haemato-oncology and solid tumors |